Johnson & Johnson

NYSE JNJ

Johnson & Johnson Market Capitalization on October 14, 2024: USD 389.01 B

Johnson & Johnson Market Capitalization is USD 389.01 B on October 14, 2024, a 2.54% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Johnson & Johnson 52-week high Market Capitalization is USD 403.02 B on September 10, 2024, which is 3.60% above the current Market Capitalization.
  • Johnson & Johnson 52-week low Market Capitalization is USD 347.64 B on May 28, 2024, which is -10.63% below the current Market Capitalization.
  • Johnson & Johnson average Market Capitalization for the last 52 weeks is USD 373.96 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NYSE: JNJ

Johnson & Johnson

CEO Mr. Joaquin Duato
IPO Date Jan. 2, 1943
Location United States
Headquarters One Johnson & Johnson Plaza
Employees 131,900
Sector Health Care
Industries
Description

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Similar companies

MRK

Merck & Co., Inc.

USD 109.69

-0.04%

BMY

Bristol-Myers Squibb Company

USD 52.67

0.90%

PFE

Pfizer Inc.

USD 29.08

-0.27%

LLY

Eli Lilly and Company

USD 930.19

-0.20%

ABBV

AbbVie Inc.

USD 195.65

0.75%

GILD

Gilead Sciences, Inc.

USD 85.05

0.12%

AMGN

Amgen Inc.

USD 324.62

-1.14%

StockViz Staff

October 16, 2024

Any question? Send us an email